// App-Quantinova.ai

: Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Researchers

Presenter

  • Jacob D. Soumerai

Principal Investigators

  • Anil Londhe

  • Guan Xing

  • Yong Mun

  • Neil E. Kay

  • Tait D. Shanafelt

  • Kari G. Chaffee

  • Richard R. Furman

  • Peter Hillmen

  • Jeff Sharman

  • John F. Seymour

  • Asher A. Chanan-Khan

  • John C. Byrd

  • Jeffrey A. Jones

  • Lucille A. Ferrante

  • Lyndah K. Dreiling

  • Mehrdad Mobasher

  • Thomas Stark

  • Vijay Reddy

  • Angela J. Howes

  • Danelle James

  • Pankaj Bhargava

  • Andrew D. Zelenetz

Medical Centers

  • Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

  • Jannsen Pharmaceuticals, Horsham, PA

  • Gilead Sciences, Inc., Foster City, CA

  • Genentech, Inc., South San Francisico, CA

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Stanford Univeresity Medical Center, Stanford, CA

  • Department of Health Sciences Research, Mayo Clinic, Rochester, MN

  • Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

  • St. James's University Hospital, Leeds, United Kingdom

  • Willamette Valley Cancer Institute and Research Center, Springfield, OR

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • Mayo Clinic, Jacksonville, FL

  • The Ohio State Univerisity, Columbus, OH

  • Pharmacyclics, Inc., Sunnyvale, CA

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • Gilead Sciences, Inc

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Idelalisib

  • ofatumumab Intravenous

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01611090

  • NCT01578707

  • NCT01569295

  • NCT01539512

  • NCT01659021

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved